Yujin Sekinaka

Dr. Yujin Sekinaka

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
YTYuki Tsujita
Yuki Tsujita
KMKanako Mitsui-Sekinaka
Kanako Mitsui-Sekinaka
KIKohsuke Imai
Kohsuke Imai
TYTzu-Wen Yeh
Tzu-Wen Yeh
NMNoriko Mitsuiki
Noriko Mitsuiki
SNShigeaki Nonoyama
Shigeaki Nonoyama

4 October 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Tineke CANTAERTTineke CANTAERT
Tineke CANTAERT
JSJean-Nicolas Schickel
Jean-Nicolas Schickel
JBJason M. Bannock
Jason M. Bannock
YNYen-Shing Ng
Yen-Shing Ng
CMChristopher Massad
Christopher Massad
EMEric Meffre
Eric Meffre
Patients with mutations in AICDA, which encodes activation-induced cytidine deaminase (AID), display an impaired peripheral B cell tolerance. AID mediates class-switch recombination (CSR) and somatic hypermutation (SHM) in B cells, but the mechanism by which AID prevents the accumulation of autoreactive B cells in blood is unclear. Here, we analyzed B cell tolerance in AID-deficient patients, patients with autosomal dominant AID mutations (AD-AID), asymptomatic AICDA heterozygotes (AID+/–), and patients with uracil N-glycosylase (UNG) deficiency, which impairs CSR but not SHM. The low frequency of autoreactive mature naive B cells in UNG-deficient patients resembled that of healthy subjects, revealing that impaired CSR does not interfere with the peripheral B cell tolerance checkpoint. In contrast, we observed decreased frequencies of SHM in memory B cells from AD-AID patients and AID+/– subjects, who were unable to prevent the accumulation of autoreactive mature naive B cells. In addition, the individuals with AICDA mutations, but not UNG-deficient patients, displayed Tregs with defective suppressive capacity that correlated with increases in circulating T follicular helper cells and enhanced cytokine production. We conclude that SHM, but not CSR, regulates peripheral B cell tolerance through the production of mutated antibodies that clear antigens and prevent sustained interleukin secretions that interfere with Treg function.

11 May 2017 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
YSYujin Sekinaka
Yujin Sekinaka
NMNoriko Mitsuiki
Noriko Mitsuiki
KIKohsuke Imai
Kohsuke Imai
MYMiharu Yabe
Miharu Yabe
HYHiromasa Yabe
Hiromasa Yabe
SNShigeaki Nonoyama
Shigeaki Nonoyama

13 May 2023 in Immunological Medicine
Verified
Journal Article
Open access
KMKunihiko Moriya
Kunihiko Moriya
KMKanako Mitsui-Sekinaka
Kanako Mitsui-Sekinaka
YSYujin Sekinaka
Yujin Sekinaka
AEAkifumi Endo
Akifumi Endo
HKHirokazu Kanegane
Hirokazu Kanegane
SNShigeaki Nonoyama
Shigeaki Nonoyama
Activated phosphatidyl inositol 3-kinase-delta syndrome (APDS) due to gain-of-function variant in the class IA PI3K catalytic subunit p110δ (responsible gene: PIK3CD) was described in 2013. The disease is characterized by recurrent airway infections and bronchiectasis. It is associated with hyper-IgM syndrome due to the defect of immunoglobulin class switch recombination and decreased CD27-positive memory B cells. Patients also suffered from immune dysregulations, such as lymphadenopathy, autoimmune cytopenia or enteropathy. T-cell dysfunction due to increased senescence is associated with a decrease in CD4-positive T lymphocytes and CD45RA-positive naive T lymphocytes, along with increased susceptibility to Epstein-Barr virus/cytomegalovirus infections. In 2014, loss-of-function (LOF) mutation of p85α (responsible gene: PIK3R1), a regulatory subunit of p110δ, was identified as a causative gene, followed in 2016 by the identification of the LOF mutation of PTEN, which dephosphorylates PIP3, leading to the differentiation of APDS1 (PIK3CD-GOF), APDS2 (PIK3R1-LOF) and APDS-L (PTEN-LOF). Since the pathophysiology of patients with APDS varies with a wide range of severity, it is crucial that patients receive appropriate treatment and management. Our research group created a disease outline and a diagnostic flow chart and summarized clinical information such as the severity classification of APDS and treatment options.

1 September 2016 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
TATakahiro Aoki
Takahiro Aoki
KKKatsuyoshi Koh
Katsuyoshi Koh
YIYuhachi Ikeda
Yuhachi Ikeda
YSYujin Sekinaka
Yujin Sekinaka
KAKosuke Akiyama
Kosuke Akiyama
RHRyoji Hanada
Ryoji Hanada
The complication of Fanconi anemia (FA) with acute leukemia is rare and challenging to treat because of high relapse rates, despite the improved outcome of hematopoietic stem cell transplantation with fludarabine-based conditioning for treating FA patients with hematological abnormalities. We added high-dose cytarabine to fludarabine-based conditioning to promote an enhanced antitumor effect and successfully subjected 4 patients with FA, including 3 with acute leukemia, to hematopoietic stem cell transplantation. All patients remain alive without treatment-related mortality or evidence of disease. Adding high-dose cytarabine to fludarabine-based conditioning may be tolerable and effective for treating FA patients with acute leukemia.

15 December 2023 in Science Advances
Verified
Journal Article
Open access
ANAkira Nishimura
Akira Nishimura
KYKazuaki Yokoyama
Kazuaki Yokoyama
TNTakuya Naruto
Takuya Naruto
CYChika Yamagishi
Chika Yamagishi
TIToshihiko Imamura
Toshihiko Imamura
MTMasatoshi Takagi
Masatoshi Takagi
Myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) has been described on the basis of its unique immunophenotype and clinical phenotype. However, there is no consensus on the characteristics for identifying this disease type because of its rarity and lack of defined distinctive molecular characteristics. In this study, multiomics analysis revealed that MNKPL is distinct from acute myeloid leukemia, T cell acute lymphoblastic leukemia, and mixed-phenotype acute leukemia (MPAL), and NOTCH1 and RUNX3 activation and BCL11B down-regulation are hallmarks of MNKPL. Although NK cells have been classically considered to be lymphoid lineage–derived, the results of our single-cell analysis using MNKPL cells suggest that NK cells and myeloid cells share common progenitor cells. Treatment outcomes for MNKPL are unsatisfactory, even when hematopoietic cell transplantation is performed. Multiomics analysis and in vitro drug sensitivity assays revealed increased sensitivity to l -asparaginase and reduced levels of asparagine synthetase (ASNS), supporting the clinically observed effectiveness of l -asparaginase.